ArticleImmunity2014
A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens.
Article in Immunity, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 103 citations in OpenAlex.
- Lipid nanoparticles as a tool to dissect dendritic cell maturation pathways.Cell reports · 2025Article
- Immune Responses of Dendritic Cells to Zoonotic DNA and RNA Viruses.Veterinary sciences · 2025Review
- The landscape of decidual immune cells at the maternal-fetal interface in parturition and preterm birth.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Can invariant Natural Killer T cells drive B cell fate? a look at the humoral response.Frontiers in immunology · 2025Review
- A structural perspective of how T cell receptors recognize the CD1 family of lipid antigen-presenting molecules.The Journal of biological chemistry · 2024Review
- invariant Natural Killer T cell therapy as a novel therapeutic approach in hematological malignancies.Frontiers in transplantation · 2024Review
- Lysosomal processing of sulfatide analogs alters target NKT cell specificity and immune responses in cancer.The Journal of clinical investigation · 2023Article
- Conventional type 1 dendritic cells protect against age-related adipose tissue dysfunction and obesity.Cellular & molecular immunology · 2022Article
- Stimulation of a subset of natural killer T cells by CD103Cell reports · 2022Article
- Harnessing invariant natural killer T cells to control pathological inflammation.Frontiers in immunology · 2022Review
- Review of Dendritic Cells, Their Role in Clinical Immunology, and Distribution in Various Animal Species.International journal of molecular sciences · 2021Review
- Reduced dose of PTCy followed by adjuvant α-galactosylceramide enhances GVL effect without sacrificing GVHD suppression.Scientific reports · 2021Article
- Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.Cancer research · 2021Article
- In Vivo Cytotoxicity by α-GalCer-transactivated NK Cells.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Identification of Two Subsets of Murine DC1 Dendritic Cells That Differ by Surface Phenotype, Gene Expression, and Function.Frontiers in immunology · 2021Article
- Natural Killer T Lymphocytes Integrate Innate Sensory Information and Relay Context to Effector Immune Responses.Critical reviews in immunology · 2021Review
- Amide-Linked C4″-Saccharide Modification of KRN7000 Provides Potent Stimulation of Human Invariant NKT Cells and Anti-Tumor Immunity in a Humanized Mouse Model.ACS chemical biology · 2020Article
- Spatial distribution of IL4 controls iNKT cell-DC crosstalk in tumors.Cellular & molecular immunology · 2020Article
- Combined proinflammatory cytokine and cognate activation of invariant natural killer T cells enhances anti-DNA antibody responses.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Myeloid and Plasmacytoid Dendritic Cells and Cancer - New Insights.Open access Macedonian journal of medical sciences · 2019Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
21 authors at 9 institutions in 6 countries.
Funding
Abstract
Many hematopoietic cell types express CD1d and are capable of presenting glycolipid antigens to invariant natural killer T cells (iNKT cells). However, the question of which cells are the principal presenters of glycolipid antigens in vivo remains controversial, and it has been suggested that this might vary depending on the structure of a particular glycolipid antigen. Here we have shown that a single type of cell, the CD8α(+) DEC-205(+) dendritic cell, was mainly responsible for capturing and presenting a variety of different glycolipid antigens, including multiple forms of α-galactosylceramide that stimulate widely divergent cytokine responses. After glycolipid presentation, these dendritic cells rapidly altered their expression of various costimulatory and coinhibitory molecules in a manner that was dependent on the structure of the antigen. These findings show flexibility in the outcome of two-way communication between CD8α(+) dendritic cells and iNKT cells, providing a mechanism for biasing toward either proinflammatory or anti-inflammatory responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.